<code id='FC88D2DF52'></code><style id='FC88D2DF52'></style>
    • <acronym id='FC88D2DF52'></acronym>
      <center id='FC88D2DF52'><center id='FC88D2DF52'><tfoot id='FC88D2DF52'></tfoot></center><abbr id='FC88D2DF52'><dir id='FC88D2DF52'><tfoot id='FC88D2DF52'></tfoot><noframes id='FC88D2DF52'>

    • <optgroup id='FC88D2DF52'><strike id='FC88D2DF52'><sup id='FC88D2DF52'></sup></strike><code id='FC88D2DF52'></code></optgroup>
        1. <b id='FC88D2DF52'><label id='FC88D2DF52'><select id='FC88D2DF52'><dt id='FC88D2DF52'><span id='FC88D2DF52'></span></dt></select></label></b><u id='FC88D2DF52'></u>
          <i id='FC88D2DF52'><strike id='FC88D2DF52'><tt id='FC88D2DF52'><pre id='FC88D2DF52'></pre></tt></strike></i>

          
          WSS
          Stock exchange
          Drew Angerer/Getty Images

          Sage Therapeutics said Monday that it may need to reduce costs, including through employee layoffs, following the Food and Drug Administration’s denial of its rapid-acting drug for major depressive disorder.

          On Friday, the agency granted market clearance for the drug, called Zurzuvae, to treat women with postpartum depression, a smaller commercial market. Sage failed to convince regulators to also approve the drug for depression, a broader condition.

          advertisement

          “We don’t agree with the FDA review,” Sage CEO Barry Greene said during an earnings call, a point he made repeatedly. “We are evaluating the [FDA’s response letter] and as soon as we can provide more clarity, we will, on what the next steps are.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          comprehensive